GSK (LON:GSK) Stock Rating Reaffirmed by Shore Capital

GSK (LON:GSK)‘s stock had its “buy” rating reiterated by stock analysts at Shore Capital in a research note issued to investors on Thursday, Digital Look reports.

A number of other research analysts also recently commented on the company. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research note on Tuesday, June 18th. Citigroup reissued a “buy” rating and issued a GBX 2,100 ($26.64) price target on shares of GSK in a research note on Monday. Barclays reaffirmed an “equal weight” rating and set a GBX 1,725 ($21.88) price objective on shares of GSK in a research report on Tuesday, May 7th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 ($24.74) target price on shares of GSK in a research report on Tuesday, June 18th. Finally, Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 ($26.64) price target on shares of GSK in a research note on Thursday. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,791.25 ($22.72).

GSK Trading Down 5.1 %

GSK stock opened at GBX 1,518 ($19.26) on Thursday. The company has a quick ratio of 0.73, a current ratio of 0.87 and a debt-to-equity ratio of 134.34. GSK has a 12 month low of GBX 1,302.60 ($16.52) and a 12 month high of GBX 1,823.50 ($23.13). The company’s fifty day simple moving average is GBX 1,688.19 and its 200-day simple moving average is GBX 1,630.16. The stock has a market cap of £61.93 billion, a P/E ratio of 1,392.66, a P/E/G ratio of 1.19 and a beta of 0.27.

Insider Transactions at GSK

In other news, insider Wendy Becker bought 446 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were acquired at an average cost of GBX 1,614 ($20.47) per share, for a total transaction of £7,198.44 ($9,131.60). 1.60% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.